News & Comments
Let’s Go Shopping
In today’s news, Incyte’s (INCY) immuno-oncology IDO1 inhibitor product Epacadostat in combination with Merck’s immuno-oncology product Keytruda® did not meet the endpoints of the trial in …
An Erroneous Interpretation of an Outstanding Achievement in CRISPR Gene Editing
A False Reason for Unwarranted Selling of CRISPR/Cas9 Gene Editing Shares CRISPRs are bacterial immune systems that contain many defense enzymes such as the Cas9 “molecular scissors,” …
Today’s Highlights
Illumina’s Contribution to Practicing Precision Medicine
When we reiterated that Illumina (ILMN) is the engine of the biotechnology evolution we meant it. We have to add, though, that the evolution made …
Novartis to Acquire AveXis. Would the Approval of AVXS-101, If Any, Impact the Sales of Ionis’ Spinraza?
NOVARTIS TO ACQUIRE AVEXIS A few months ago, Novartis (NVS) CEO agreed to cash out of the company’s consumer health joint venture with …
Yes, the Biotech Evolution Is Speeding. See Also: Allogene Therapeutics, Pfizer and Cellectis
THE BIOTECH EVOLUTION: AN UNPARALLELED SPEED The Tremendous Regret Investors Will Feel If They Sell the Best of the Best Biotechnology Firms Only …
Why Investors Caused a Selloff of Alnylam’s Stock
Alnylam (ALN) is probably experiencing a stock selloff following the announcement of successful results from Pfizer's (PFE) drug tafamidis. …
Recent Popular Posts:
Bellicum Pharmaceuticals: The FDA Lifted the Clinical Hold on BPX-501 Clinical Trial
Bellicum Pharmaceuticals (BLCM): The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on studies of BPX-501 in the U.S. The decision follows consultation with the FDA and agreement on amendments …
Illumina’s Contribution to Practicing Precision Medicine
When we reiterated that Illumina (ILMN) is the engine of the biotechnology evolution we meant it. We have to add, though, that the evolution made possible by Illumina’s sequencers and next-generation sequencing (NGS) …
Bellicum Pharmaceuticals: The FDA Lifted the Clinical Hold on BPX-501 Clinical Trial
Bellicum Pharmaceuticals (BLCM): The U.S. Food and Drug Administration (FDA) has lifted the clinical hold on studies of BPX-501 in the U.S. The decision follows consultation with the FDA and …
| News & Comments